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A host cytidine deaminase, APOBEC3G (A3G), inhibits replication of human immunodeficiency virus type 1 (HIV-1) by incorporating into
virions in the absence of the virally encoded Vif protein (Δvif virions), at least in part by causing G-to-A hypermutation. To gain insight into the
antiretroviral function of A3G, we determined the quantities of A3G molecules that are incorporated in Δvif virions. We combined three
experimental approaches-reversed-phase high-pressure liquid chromatography (HPLC), scintillation proximity assay (SPA), and quantitative
immunoblotting-to determine the molar ratio of A3G to HIV-1 capsid protein in Δvif virions. Our studies revealed that the amount of the A3G
incorporated intoΔvif virions was proportional to the level of its expression in the viral producing cells, and the ratio of the A3G to Gag in theΔvif
virions produced from activated human peripheral blood mononuclear cells (PBMC) was approximately 1:439. Based on previous estimates of the
stoichiometry of HIV-1 Gag in virions (1400–5000), we conclude that approximately 7 (±4) molecules of A3G are incorporated into Δvif virions
produced from human PBMCs. These results indicate that virion incorporation of only a few molecules of A3G is sufficient to inhibit HIV-1
replication.
Published by Elsevier Inc.Keywords: APOBEC3G virion incorporation; Peripheral mononuclear blood cells; Cytidine deamination; Scintillation proximity assay; Δvif virionsIntroduction
High rates of G-to-A substitutions were first observed to occur
in retroviral genomes in a spleen necrosis virus and named
hypermutation by the authors (Pathak and Temin, 1990); later, G-
to-A hypermutationswere observed inHIV-1 genomes (Vartanian
et al., 1991). Recently, a host cytidine deaminase APOBEC3G
(A3G)was identified to be responsible for inhibition of replication
of Δvif virions in restricted cell lines (Sheehy et al., 2002).
Subsequently, A3G was found to induce G-to-A hypermutations
in HIV-1 genomes (Lecossier et al., 2003; Mangeat et al., 2003;
Zhang et al., 2003).During reverse transcription,A3Gdeaminates
deoxycytidines in minus-strand DNA to form deoxyuridine,
resulting inG-to-A hypermutation and viral inactivation (Harris et
al., 2003; Mangeat et al., 2003; Zhang et al., 2003). Although⁎ Corresponding author. Fax: +1 301 846 6013.
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doi:10.1016/j.virol.2006.10.036hypermutation is thought to be responsible for viral inactivation, a
recent report showed that the antiviral activity of A3G could be
independent of its cytidine deaminase activity (Newman et al.,
2005), indicating that the mechanism of its antiviral activity may
bemore complex than previously believed. A3G expression in the
virus producer cells results in its incorporation into HIV-1 and this
virion packaging plays an important role in A3G's antiretroviral
function (Kao et al., 2003; Marin et al., 2003). A3G is an RNA-
binding protein, and we as well as other groups recently showed
that it is packaged into HIV-1 virions through its interactions with
RNA (Svarovskaia et al., 2004; Zennou et al., 2004), whereas
other groups have suggested that interactions between A3G and
NC are essential for virion incorporation (Alce and Popik, 2004;
Cen et al., 2004; Luo et al., 2004; Schafer et al., 2004). HIV-1
encodes Vif, which can overcome the antiviral activity of A3G by
inducing its proteolysis through the proteasomal degradation
pathway, thereby preventing A3G packaging into virions
(Conticello et al., 2003; Kao et al., 2003; Mariani et al., 2003;
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absence of Vif, the endogenousA3G is packaged intoΔvif virions
and the replication of these virions is suppressed (Sheehy et al.,
2002).
Determination of the amount of A3G packaged inΔvif virions
may shed light on the mechanism(s) by which it inhibits HIV-1
replication. While G-to-A hypermutation is generally thought to
inactivate viral genomes through lethal mutagenesis, the presence
of uridines in the minus-strand DNA has also been shown to
inhibit initiation of plus-strand DNA synthesis (Klarmann et al.,
2003). A recent study also showed that A3G inhibited viral DNA
synthesis independent of its cytidine deamination activity (Bishop
et al., 2006; Newman et al., 2005). Most studies of A3G's effects
on viral infectivity are performed using transient transfection of
A3G-expressing plasmids, and may be complicated by over-
expression of A3G in the virus producer cells compared to the
levels of A3G that are likely to exist in the natural targets of HIV-1
infection. Overloading of A3G protein in virions could result in
inhibition of viral replication through mechanisms that do not
operate during natural HIV-1 infection. Therefore, determining
the amounts ofA3G incorporated intoΔvif virions and comparing
these levels to those found in virions produced from transfected
cells could provide insight into the mechanisms by which A3G
inhibits HIV-1 replication. Determining the stoichiometry of A3G
in Δvif virions may also provide insights into the nature of
interactions between A3G and viral RNA or proteins, whether
A3G acts catalytically or as a physical barrier to reverse
transcription, and the efficiency with which Vif must prevent its
incorporation into virions.
The results of our studies using reversed-phase high-
pressure liquid chromatography (HPLC), quantitative immu-
noblotting, and cytidine deaminase assays indicate that the
A3G levels in Δvif virions are approximately 0.228% of HIV-
1 Gag, providing an A3G:Gag ratio of 1:439. Thus, based onFig. 1. HPLC analysis and cytidine deaminase activities of HIV-GFPΔvif virions
produced from 293T cells cotransfected with 0, 2, 4, or 8 μg of pcDNA-APO3G
and from activated CD4+T cells. Virion preparation is described in Materials and
methods. (A) Protein elution profiles detected at 280 nm. Proteins eluted from
the column of acetonitrile gradient were analyzed by SDS-PAGE to confirm the
complete separation by HPLC; the identities of the proteins were confirmed by
protein sequencing, immunoblot analysis and amino acid analysis. An example
of the immunoblotting analysis performed to confirm the identity of the peak
containing A3G is shown in the inset. Peak names are shown at the bottom of the
HPLC profiles. After isolation and quantitation of virion-associated A3G and
p24 CA, the A3G to CA molar ratio was determined. (B) Correlation between
A3G protein incorporated into HIV-GFPΔvif virions and the amount of pcDNA-
APO3G cotransfected. The A3G to CA molar ratios as a % of CA are plotted on
the y axis, and the amount of pcDNA-APO3G used in cotransfection during
production of HIV-GFPΔvif virions are plotted on the x-axis. (C) Relative A3G
activities in HIV-GFPΔvif virions. HIV-GFPΔvif virions harvested from 293T
cells cotransfected with 8, 4, 2, 1, 0.5 and 0 μg of pcDNA-APO3G and from
three preparations of human CD4+T cells were analyzed, and the relative A3G
activities in virions containing 1 ng of p24 CA were determined. The A3G
activity of HIV-GFPΔvif virions produced from 293T cells transfected with 2 μg
pcDNA-APO3G was set as 100%. The linear portion of the standard curve is
shown in a rectangle of dashed lines. Linear regression analysis indicating the
best fit is shown as a solid black line, and the R2 value is indicated. The average
relative A3G activity of 1 ng p24 CA of HIV-GFPΔvif virions harvested from
human CD4+T cells is represented by a green dot labeled with an arrow.current estimates of HIV-1 Gag molecules per virion (1400–
5000) (Briggs et al., 2004; Layne et al., 1992; Zhu et al.,
2003), incorporation of very few enzymatically active A3G
molecules (7±4) is sufficient to potently inhibit HIV-1
replication.
Results
Quantitative HPLC determination of A3G:Gag ratio in Δvif
virions
To determine the A3G:Gag ratio in Δvif virions, HPLC was
used to separate and quantify virion proteins (Fig. 1). HPLC
allowed viral proteins to be isolated, characterized, and
quantified in one combined procedure, providing accurate
measurement of the protein composition of the virus. pHDV-
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proteins as well as EGFP, but does not express Vif, Vpr, Vpu,
Env, or Nef proteins. Cotransfection of 293T cells with pHDV-
EGFP and 8, 4, or 2 μg of pcDNA-APO3G, a plasmid that
expresses A3G, resulted in the production of HIV-GFPΔvif
virions containing A3G, which were isolated by density
ultracentrifugation, lysed, and subjected to HPLC separation.
The HPLC fractions containing p24 CA and A3G proteins were
identified by silver staining and immunoblotting; subsequently,
the identified fractions were subjected to mass spectrometry and
protein sequence analyses. The result showed that the height of
the A3G peak was directly proportional to the amount of
pcDNA-APO3G used in each cotransfection. In addition,
consistent with the very low expression levels of A3G in
293T cells, A3G was not detectable in HIV-GFPΔvif virions
produced from 293T cells in the absence of cotransfection with
pcDNA-APO3G. To obtain an accurate ratio of the amount of
A3G and Gag in HIV-GFPΔvif virions produced from cells
transfected with 8 μg of pcDNA-APO3G, we subjected a
portion of the corresponding HPLC fractions to automated
amino acid analysis. The precise amount of the protein in the
sample can be determined by comparing it to a set of known
standards. The results of amino acid analysis with reference
amino acid standards revealed that the average value for the Gag
proteins (average of MA, CA, NC, and p6) was 206 nanomoles
and the value for A3G was 11 nanomoles in this sample,
indicating that the moles of A3G were 5.3% of the moles of CA,
which is equivalent to the A3G:Gag ratio. In addition, the amino
acid stoichiometry observed closely matched the expected
compositions, indicating that both A3G and CA samples were
predominantly pure. Because UV absorbance is directly
proportional to the amount of protein, we determined the
amount of A3G and CA protein in the 4 and 2 μg A3G
cotransfection samples by comparing the integrated peak
heights of the CA and A3G fractions of these samples to
those corresponding peaks observed for the HIV-GFPΔvif
virion samples produced from cells transfected with 8 μg of
pcDNA-APO3G. These quantitations were used to calculate the
A3G:Gag molar ratios for each HIV-GFPΔvif virion sample
(Fig. 1). The results showed that the moles of A3G in HIV-
GFPΔvif virions produced from 8, 4 and 2 μg of pcDNA-
APO3G cotransfected 293T cells were 5.3%, 2.7%, and 1.2%,
respectively, of the moles of Gag (Fig. 1A). The results also
indicated that the amounts of A3G in HIV-GFPΔvif virions
were directly proportional to the amounts of cotransfected
pcDNA-APO3G (Fig. 1B).
Quantitation of A3G activity in HIV-GFPΔvif virions produced
from primary CD4+T cells
We sought to determine whether the A3G activities in
HIV-GFPΔvif virions correlated with the A3G protein levels
determined by HPLC analysis, and the relative A3G
enzymatic activities in primary CD4+T cell-derived and
293T-derived HIV-GFPΔvif virions. We quantified the A3G
enzymatic activities HIV-GFPΔvif virions by using an A3G-
specific scintillation proximity assay (SPA) that we reportedpreviously (Svarovskaia et al., 2004). The assay uses an
oligonucleotide substrate that is specific for A3G but not
APOBEC3F (Harris and Liddament, 2004) and is unable to
detect cytidine deaminase activity from cells transfected with
human APOBEC3F, human APOBEC3B, and murine APO-
BEC3 (data not shown). Thus, the assay primarily measured
the cytidine deamination activity of A3G in the samples
tested.
The amounts of primary CD4+T cell-derived and 293T cell-
derived HIV-GFPΔvif virions were determined by quantifying
the amounts of p24 CA protein by ELISA, and the A3G
activities associated with HIV-GFPΔvif virions containing 1 ng
of p24 CA were compared. Consistent with the HPLC analysis
(Fig. 1A), the A3G enzymatic activities in the HIV-GFPΔvif
virions produced from these cells were proportional to the
amounts of pcDNA-APO3G used for transfection (Fig. 1C).
Linear regression analysis of the A3G activities observed for
cells transfected with 4, 2, 1, and 0.5 μg of pcDNA-APO3G
showed an excellent fit with an R2 value of 0.987. The primary
CD4+T cell-derived HIV-GFPΔvif virions contained an average
of 15.7% of the A3G enzymatic activity present in the HIV-
GFPΔvif virions produced from 293T cells transfected with
2 μg of pcDNA-APO3G (Table 1). The A3G activities in the
primary CD4+T cell-derived HIV-GFPΔvif virions were also
significantly higher than the mock-infected negative controls
(Table 1; P<0.001).
Quantitative immunoblotting analysis of A3G in Δvif virions
produced from human PBMCs
We sought to determine the A3G:Gag ratio in virions
produced in the presence of all viral proteins except Vif to rule
out the possibility that the absence of viral proteins Vpr, Vpu,
Env, and Nef influenced A3G packaging in HIVΔvif virions.
We used NL43Δvif, an HIV-1 genome that expresses all viral
proteins except Vif, to produce NL43Δvif virions from PBMCs
and compared the amounts of A3G incorporated to those
present in HIV-GFPΔvif virions produced from 293T cells
transfected with 2 μg of pcDNA-APO3G. Although the HPLC
analysis provided an accurate measurement of the A3G:Gag
ratios, the method required large quantities of virions (Zhu et al.,
2003). Because it was impractical to produce such large
quantities of virions from activated human PBMCs, we used
quantitative immunoblotting analysis, a method requiring >10-
fold less virions, to compare the amounts of A3G protein inΔvif
virions produced from the human PBMCs and transfected 293T
cells. To obtain an accurate comparison, the lysed HIV-GFPΔvif
virion preparation obtained from 293T cells transfected with
pcDNA-APO3G were serially diluted to contain 50, 25, 12.5,
and 6.25 ng of p24 CA and compared to PBMC-derived
NL43Δvif virion preparations containing 100 ng of p24 CA
(Fig. 2A). We compared the 293T-derived and PBMC-derived
A3G bands of similar intensities to maximize accuracy of
quantitation. The amount of A3G protein in NL43Δvif virions
containing 100 ng of p24 CA produced a band that was of
similar intensity to the band produced from 293T-derived
virions containing 25 ng of p24 CA (Fig. 2B, bands indicated by
Table 1
Relative A3G activities in HIV-GFPΔvif virions sample
Cells pcDNA-APO3Ga Viruses p24 CA No. of
experiments
Relative A3G activity
(%) Average b±S.E.
t test c
P value
[V-A3GCD4+T]/
[V-A3G2 μg]
d
293T cells 8 μg HIV-GFPΔvif 1 ng 3 199.7±4.5
4 μg 1 ng 3 161.1±4.4
2 μg 1 ng 3 100±0.0
1 μg 1 ng 3 54.1±8.5
0.5 μg 1 ng 3 35.8±6.0
0 1 ng 3 6.1±2.0
CD4+T cell donor #1 HIV-GFPΔvif 1 ng 3 15.7±4.0 <0.001 15.7%
Mock Equal vol. e 3 6.8±3.0
CD4+T cell donor #2 HIV-GFPΔvif 1 ng 3 15.7±0.1 <0.001 15.7%
Mock Equal vol. 3 6.4±2.0
CD4+T cell donor #3 HIV-GFPΔvif 1 ng 3 15.7±5.0 <0.001 15.7%
Mock Equal vol. 3 8.2±2.0
Average [V-A3GCD4+T]/[V-A3G2 μg] ratio 15.7%
a Amount of pcDNA-APO3G used to transfect 293T cells.
b A3G activity in virions harvested from 2 μg pcDNA-APO3G transfected 293T was set as 100%. The average cpm for samples containing 1 ng p24 CA of HIV-
GFPΔvif virions harvested from 293T cells transfected with 2 μg of pcDNA-APO3G was 19,385; the average cpm for samples without any HIV-GFPΔvif virions was
50.
c The t tests were performed to compare A3G activities in viruses produced from human CD4+T cells with A3G activities in culture supernatant (mock infected
sample) of the CD4+T cells from the same donor.
d The[V-A3GCD4+T]/[V-A3G2 μg] ratio was defined as the ratio of A3G activities in ng p24 CA of CD4
+T cell-derived HIV-GFPΔvif virions and the A3G activities
in 1 ng of p24 CA of HIV-GFPΔvif virions produced from 293T cells transfected with 2 μg of pcDNA-APO3G.
e Because the mock infected samples did not contain p24 CA (data not shown), volumes of these samples equivalent to the volume of culture supernatant from
PBMCs producing NL43Δvif and containing 1 ng of p24 CA were used in the SPA.
250 H. Xu et al. / Virology 360 (2007) 247–256arrows). Quantitation of the band intensities was performed and
the A3G band produced with 293T-derived HIV-GFPΔvif
virions containing 100 ng of p24 CAwas set to 100%. The A3G
protein band intensities of the PBMC-derived NL43Δvif virions
[67%/100 ng] and the 293T-derived HIV-GFPΔvif virions
[75%/25 ng] were used to calculate that the PBMC-derived
NL43Δvif virions contained approximately 22% of the A3G
present in 293T-derived HIV-GFPΔvif virions (see Fig. 2B,
legend). Thus, the amounts of A3G packaged in Δvif virions
were proportional to the amounts of A3G expressed in the virus
producer cells. In contrast to the NL43Δvif virions, the wild
type NL43 virions contained much lower quantities of A3G
(13% vs. 67% per 100 ng of p24 CA). This observation
confirmed that expression of the Vif protein from the wild type
NL43 substantially reduced the amount of A3G that was
incorporated into the PBMC-derived virions.
Quantitation of A3G enzymatic activity in NL43Δvif virions
produced from human PBMCs
Next, we compared the A3G activities present in NL43 and
NL43Δvif virions produced from activated PBMCs to those
from 293T cells transfected with 2 μg of pcDNA-APO3G
(Table 2 and Fig. 2B). Similar to the analysis of A3G activities
in cell lysates, we generated a standard curve by measuring
A3G activities in serial dilutions of HIV-GFPΔvif virions
produced from 293T cells transfected with 2 μg of pcDNA-
APO3G and 20 μg pHDV-EGFP. The standards consisted of
HIV-GFPΔvif virion lysates containing 1, 0.5, 0.25 and
0.125 ng of p24 CA harvested from the cotransfected 293T
cells; the negative control contained 2 ng of p24 CA from HIV-
GFPΔvif virions produced from 293T cells in the absence ofpcDNA-APO3G. The A3G activity in the HIV-GFPΔvif viral
lysate containing 1 ng of p24 CAwas set to 100% (Table 2 and
Fig. 2B). The results of SPA showed that the relative A3G
enzymatic activities observed in 293T-derived HIV-GFPΔvif
lysates containing 1, 0.5, 0.25, and 0.125 ng of p24 CA were
proportional to the amount of viral proteins used in the assay.
Linear regression analysis of these activities indicated an
excellent fit and provided an R2 value of 0.996 (dashed box in
Fig. 3B and Table 2). The HIV-GFPΔvif virion lysates
containing 2 ng of p24 CA produced from control 293T cells
contained only 4.2% of the A3G activity observed in 1 ng of
p24 CA from HIV-GFPΔvif virions produced in the presence of
pcDNA-APO3G (Table 2).
We then determined the A3G activities present in three
preparations of PBMC-derived NL43 and NL43Δvif virions
containing 2 ng of p24 CA and compared these activities to
those present in 293T-derived HIV-GFPΔvif virions. The A3G
activities in NL43Δvif virion lysates containing 2 ng of p24 CA
ranged from 22.9 to 27.7% of the activities in 293T-derived
HIV-GFPΔvif virion lysates containing 1 ng of p24 CA (Table
2, samples labeled NL43Δvif and Fig. 2B, green dot labeled
with arrow). The A3G activities in the PBMC-derived
NL43Δvif virions were within the linear range of the assay
(Fig. 2B). The ratio of A3G activity in PBMC-derived
NL43Δvif virions [V-A3GPBMC] to the A3G activity in HIV-
GFPΔvif virions produced from 293T cells transfected with
2 μg of pcDNA-APO3G [V-A3G2 μg] was determined by using
the activities observed in 0.25 ng of p24 CA from the 293T-
derived virions, because these activities were within the linear
range and closest to the activities in the PBMC-derived virions.
The average [V-A3GPBMC]/[V-A3G2 μg] ratio was 19.0% (Table
2). Thus, the A3G activity in PBMC-derived NL43Δvif virions
Fig. 2. Quantitative immunoblotting analysis and cytidine deaminase activities
of A3G in HIV-1 virions. (A) Quantitative immunoblotting analysis. HIV-
GFPΔvif virions were produced from 293T cells cotransfected with 2 μg of
pcDNA-APO3G and 20 μg of pHDV-EGFP; NL43 and NL43Δvif virions were
produced from PBMCs. The samples contained 50, 25, 12.5 and 6.25 ng of p24
CA of 293T derived HIV-GFPΔvif virions and 100 ng p24 CA of NL43 and
NL43Δvif virions produced from PBMCs. The A3G protein was detected using
an anti-A3G polyclonal antibody and the intensities of the bands were quantified
by QuantityOne software (Bio-Rad). The intensity of the A3G band detected
from 293T-derived HIV-GFPΔvif virions containing 50 ng of p24 CAwas set to
100%. The amount of A3G protein in the PBMC-derived NL43Δvif virions as a
percentage of the amount of A3G in the 293T-derived HIV-GFPΔvif virions was
calculated using the bands with similar intensities (indicated by arrows) as
follows: 67% A3G/100 ng of PBMC-derived p24 CA/75% A3G/25 ng of 293T-
derived p24 CA×100%=22%. (B) Determination of A3G activities. in Δvif
virions. Standards contained 1, 0.5, 0.25 and 0.125 ng p24 CA of HIV-GFPΔvif
virions harvested from 293T cells transfected with 2 μg pcDNA-APO3G. The
linear portion of the standard curve is shown in a rectangle of dashed lines.
Linear regression analysis indicating the best fit is shown as a solid black line,
and the R2 value is indicated. The average relative A3G activity in 2 ng of p24
CA of NL43Δvif virions harvested from human PBMCs is shown as a green dot
labeled with an arrow.
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quantitative immunoblotting (Fig. 2A).
We also determined the A3G activities in PBMC-derived
wild type NL43 virions (Table 2). The A3G activities in PBMC-
derived NL43 virion lysates containing 2 ng of p24 CA ranged
from 6.2 to 7.2% of the A3G activity in 293T-derived HIV-
GFPΔvif virion lysates containing 1 ng of p24 CA, indicating
that expression of Vif from wild type NL43 in the PBMCs
significantly reduced the A3G activity in the virions compared
to the A3G activities in the NL43Δvif virions. Finally, we
determined the A3G activity present in culture supernatants of
mock-infected samples (Table 2). Volumes of culture super-
natants equivalent to those containing 2 ng of p24 CA in
NL43Δvif samples were used to determine the A3G activities;
in equivalent volumes of culture supernatants, the A3G
activities in the mock-infected samples ranged from 5.2 to7.4% compared to the activities present in 293T-derived HIV-
GFPΔvif virion lysates containing 1 ng of p24 CA (Table 2).
Therefore, the A3G activities in NL43Δvif virions were
approximately three to fourfold higher than the wild type
NL43 virions and the mock-infected samples.
Quantitative immunoblotting analysis of A3G expression in
human PBMCs
Because the HPLC analysis indicated that A3G expression
levels in the virus producer cells were directly proportional to
the amounts of A3G incorporated into virions, we sought to
determine the amounts of A3G in human PBMCs, the natural
target cells of HIV-1 infection. We used quantitative immuno-
blotting analysis to compare A3G expression levels in activated
human PBMCs to those in 293T cells transfected with 2 μg
pcDNA-APO3G (Fig. 3A). To obtain an accurate comparison,
the lysates obtained from 293T cells transfected with pcDNA-
APO3G were serially diluted to contain 1, 0.5, 0.25, and
0.125 μg of total protein and compared to 1 and 2 μg of cell
proteins obtained from activated PBMCs. In addition, because
of the relatively narrow linear dynamic range of Western
blotting analysis, we compared the 293T-derived and PBMC-
derived A3G bands of similar intensities to maximize accuracy
of quantitation. The amount of A3G protein in 1 μg of PBMC
protein produced a band that was of similar intensity to the band
produced in 0.25 μg of 293T cell protein (Fig. 3A, bands
indicated by arrows). Quantitation of the band intensities was
performed and the A3G band produced with 1 μg of 293T cell
protein was set to 100%. The A3G protein band intensities in
the activated human PBMCs [43%/1 μg] and the transfected
293T cells [36%/0.25 μg] were used to determine that the
PBMCs contained approximately 30% of the A3G present in
293T cells transfected with 2 μg of pcDNA-APO3G (see Fig.
2A, legend).
Quantitation of A3G enzymatic activity in human PBMCs
In order to accurately measure the A3G activity in human
PBMCs, we generated a standard curve by serially diluting total
cellular protein harvested from the 293T cells transfected with
2 μg pcDNA-APO3G and 20 μg pHDV-EGFP (Table 3 and Fig.
3B). The standards contained 1.8, 0.9, 0.45, 0.225, 0.113 and
0.056 μg of total protein from the transfected 293T cells; the
293T cell control contained 1.8 μg of protein from 293T cells
transfected with only 20 μg of pHDV-EGFP. The A3G
enzymatic activity observed in 1.8 μg of cell protein obtained
from the transfected 293T cells was set to 100% (Table 3 and
Fig. 3B). The relative A3G enzymatic activities observed in
0.225, 0.113 and 0.056 μg of the transfected 293T cell proteins
were proportional to the amount of cell protein used in the assay.
Linear regression analysis of these activities indicated an
excellent fit and provided an R2 value of 0.988, indicating that
within this range, the enzymatic activity measurements were
proportional to the amount of enzyme added (Fig. 3B, dashed
box and Table 3). The A3G activity in the 293T cell control was
only 1.5% of the 1.8 μg standard (Table 3).
Table 2
Relative A3G activity in NL43 and NL43Δvif virions
Samples No. of
experiments
Relative A3G
activity a (%)
Average b±SE
t test b
P value
[V-A3GPBMC]/
[V-A3G2 μg]
c
Viruses ng p24 CA
293T cells cotransfected
with 2 μg of pcDNA-APO3G
1 ng 6 100.0±0.0
0.5 ng 6 49.6±3.9
0.25 ng 6 16.6±1.1
0.125 ng 6 7.8±0.3
293T cells HIV-GFPΔvif 2 ng 6 4.2±0.2
PBMC donor #1 NL43Δvif 2 ng 3 25.1±1.0 0.002 18.9%
NL43 2 ng 4 6.6±0.3
Mock Equal vol. d 3 7.4±0.9
PBMC donor #2 NL43Δvif 2 ng 3 27.7±2.0 <0.001 20.9%
NL43 2 ng 4 6.2±0.1
Mock Equal vol. 3 6.6±0.8
PBMC donor #3 NL43Δvif 2 ng 3 22.9±0.8 <0.001 17.3%
NL43 2 ng 4 7.2±0.3
Mock Equal vol. 3 5.2±0.3
Average [V-A3GPBMC]/[V-A3G2 μg] ratios 19.0%
a A3G activity in HIV-GFPΔvif virions containing 1 ng of p24 CA that were produced from 293T cells transfected with 2 μg pcDNA-APO3G was set as 100%. The
average cpm for samples containing 1 ng of p24 CA from 293T-derived virions was 42,881; the average cpm for samples without any HIV-GFP virions was 39.
b The t tests were performed to compare A3G activities in PBMC-derived virions with A3G activities in culture supernatants of mock-infected PBMCs.
c The ratio of A3G activity in NL43Δvif virions produced from PBMCs [V-A3GPBMC] to A3G activity in HIV-GFPΔvif virions produced from 293T cells
transfected with 2 μg of pcDNA-APO3G [V-A3G2 μg] was calculated by comparing the A3G activities in 2 ng of p24 CA from PBMC-derived NL43Δvif virions
with the A3G activity in 0.25 ng of p24 CA from 293T-derived virions, because the A3G activity in this 293T-derived virion sample was within the linear portion
of the standard curve and closest to the A3G activity in the PBMC-derived virion samples. For example, the [V-A3GPBMC]/[V-A3G2 μg] for PBMC donor #1-
derived NL43Δvif virions was calculated as follows: 25.1%/2 ng of p24 CA from the PBMC-derived virions ÷ 16.6%/0.25 ng of p24 CA from the 293T-derived
virions ×100%=18.9%.
d Because the mock infected samples did not contain any detectable p24 CA (data not shown), volumes of these samples equivalent to the volume of culture
supernatant from PBMCs producing NL43Δvif virions and containing 2 ng of p24 CA were used in the SPA.
252 H. Xu et al. / Virology 360 (2007) 247–256Next, the A3G activities present in 0.45 μg of protein from
three activated PBMC preparations were compared to those
present in the transfected 293T cells. The A3G activities in
0.45 μg of PBMC cell protein ranged from 26.9 to 32.3% of the
activity in 1.8 μg of cell protein from 293Tcells transfected with
2 μg of pcDNA-APO3G (Table 3 and Fig. 3B, green dot labeled
with arrow). The A3G activities in the PBMCs were within the
linear range of the assay (Fig. 3B). The ratio of A3G activity in
PBMCs [C-A3GPBMC] to the A3G activity in 293T cells
transfected with 2 μg of pcDNA-APO3G [C-A3G2 μg] was
determined using the A3G activities observed in 0.113 μg of the
transfected 293T cell protein, because these activities were
within the linear range and closest to the activities in the
PBMCs. The average [C-A3GPBMC]/[C-A3G2 μg] ratio was
26.9% (Table 3). Thus, the A3G activity in PBMCs was
proportional to the A3G protein level in PBMCs (30%) as
determined by quantitative immunoblotting (Fig. 3A).
Very little A3G protein in culture supernatants is associated
with microvesicles
Microvesicles are protein-laden particles that have a density
and size that is similar to HIV-1 virions (Bess et al., 1997;
Gluschankof et al., 1997); as a result, microvesicles can be present
in the density purified HIV-1 preparations (Trubey et al., 2003).
To determine if the A3G enzymatic activity was associated with
Δvif virions rather than contaminating microvesicles, we digested
HIV-GFPΔvif virion preparations from human primary CD4+T
cells with subtilisin (Fig. 4, labeled Treated), a procedure thatremoves more than 95% of the contaminating microvesicle-
associated proteins (Ott et al., 2000). We also performed mock-
digestion on these HIV-GFPΔvif virion preparations (labeled
Mock) as a negative control. The results showed that the cytidine
deaminase activities in subtilisin-digested samples were not
significantly different from the mock-digested negative controls
(P=0.27, t test). These results confirmed that very little of the
A3G enzymatic activity was associated with microvesicles.
The A3G:Gag ratio and stoichiometry of A3G in
PBMC-derived NL43Δvif virions
The results of the HPLC and SPA were used to calculate
the A3G:Gag molar ratio in PBMC-derived NL43Δvif
virions as summarized in Table 4. Briefly, the A3G as a
% of Gag in NL43Δvif virions was calculated by multiplying
the ratio of A3G activities in PBMC-derived and 293T-
derived Δvif virions ([V-A3GPBMC]/[V-A3G2 μg]=19.0%)
with the A3G as a % of Gag determined by HPLC in Δvif
virions produced from 293T cells transfected with 2 μg of
pcDNA-APO3G ([V-A3G2 μg]/Gag=1.2%). The product of
these two ratios provided a [V-A3GPBMC]/Gag percentage of
0.228%, which is equivalent to an A3G:Gag molar ratio of
1:439 (Table 4).
Discussion
We combined three different experimental approaches –
HPLC, quantitative immunoblotting analysis, and A3G cytidine
Fig. 3. Quantitative immunoblotting analysis and cytidine deaminase activities
of A3G in PBMCs and 293T cells. (A) Quantitative immunoblotting analysis of
A3G in extracts of PBMCs and 293T cells cotransfected with 2 μg of pcDNA-
APO3G and 20 μg of pHDV-EGFP. The samples contained 1, 0.5, 0.25 and
0.125 μg of cellular protein harvested from the transfected 293T cells and 2 and
1 μg of cellular protein harvested from human PBMCs. The A3G protein was
detected using an anti-A3G polyclonal antibody and the intensities of the bands
were quantified by QuantityOne software (Bio-Rad). The intensity of the A3G
band containing 1 μg of cellular protein of the transiently transfected 293T cells
was set to 100%. The amount of A3G protein in PBMCs as a % of the amount of
A3G in the transfected 293T cells was calculated using the bands with similar
intensities (indicated by arrows) as follows: 43% A3G/1 μg of PBMC protein/
36% A3G/0.25 μg of 293T cell protein×100%=30%. (B) Relative A3G
activities in PBMCs. Standards contained 1.8, 0.9, 0.45, 0.225, 0.113 and
0.056 μg of cellular protein isolated from 293T cells transfected with 2 μg of
pcDNA-APO3G. The linear portion of the standard curve is shown in a
rectangle of dashed lines. Linear regression analysis indicating the best fit is
shown as a solid black line, and the R2 value is indicated. The average relative
A3G activity of 0.45 μg cellular protein harvested from human PBMCs is shown
as a green dot labeled with an arrow.
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virions. First, we determined A3G:Gag ratio in 293T-derived
Δvif virions using HPLC; second, we quantified the amounts
of A3G protein in Δvif virions by immunoblotting analysis;
and third, we determined the ratio of A3G enzymatic activities
in 293T- and PBMC-derived Δvif virions. We then calculated
the A3G:Gag ratio in PBMC-derived Δvif virions by multi-
plying these two ratios to be approximately 1:439. The
stoichiometry of Gag molecules per virion has been reported
to be 1,400 (Zhu et al., 2003) and 5,000 (Briggs et al., 2004).
The estimated A3G:Gag ratio of 1:439 and the reported range
of 1,400 to 5,000 gag molecules per virion indicates that
approximately 7±4 (3–11) A3G molecules are incorporated
into each Δvif virion.
Several observations indicate that the A3G enzymatic
activities provide an accurate measurement of the amount of
A3G protein incorporated in the PBMC-derived Δvif virions.
First, the cytidine deaminase assay showed an excellent linearrange when serial dilutions of 293T-derived Δvif virions
containing A3G were analyzed. To maximize the precision of
quantitation, we determined the A3G activities in PBMC-
derived Δvif virions within the linear range of the assay.
Second, the A3G activity determinations (Average 19.0%) were
in agreement with the A3G protein levels quantified by
immunoblotting (22%). Third, the cytidine deaminase assay
exhibited a low 4% background for 293T-derived Δvif virions
produced in the absence of pcDNA-APO3G, indicating that the
assay has high sensitivity. Finally, wild type virions produced in
the presence of Vif contained fourfold less A3G activity as
expected, indicating that the assay can readily quantify Vif-
induced reduction in A3G packaging.
The results of these studies demonstrate that virion
incorporation of A3G is proportional to the amount of A3G
expressed in the virion producing cells. The HPLC analysis
indicated that the A3G:Gag ratio in virions produced from
293T cells transfected with 8 μg of pcDNA-APO3G was
approximately 1:19. This result showed that when a HIV-1
vector:pcDNA-APO3G molar ratio of 1:0.8 is used to
cotransfect 293T cells, the amount of A3G packaging is
about 30-fold higher (74 to 264 A3G molecules/virion) than
that present in virions produced from activated PBMCs. Thus,
the conditions of the cotransfection assays could lead to a
great excess of A3G incorporation into virions, potentially
leading to inhibition of viral replication by mechanisms that
are not relevant to natural HIV-1 infection.
Previous observations that Δvif virions are replication
defective in PBMCs (Madani and Kabat, 1998; Simon et al.,
1998; von Schwedler et al., 1993), and our results that only
7±4 molecules of A3G are packaged in PBMC-derived
virions indicate that virion incorporation of only a few
molecules of A3G is sufficient to potently inhibit HIV-1
replication. Based on an average of seven A3G molecules
per virion and a Poisson distribution, the frequency of
virions lacking any A3G is approximately 0.09%. This
expected low frequency of virions lacking A3G is more than
sufficient to account for the observed 10-to 100-fold
reduction in infectious titers of Δvif virions in restricted
cell lines (Borman et al., 1995; Gaddis et al., 2003).
In addition to A3G, APOBEC3F is also packaged into
virions (Bishop et al., 2004; Liddament et al., 2004; Zheng et
al., 2004). The relative contributions of these two antiviral
proteins to inhibition of viral replication are not known. In
future studies, it will be important to determine the stoichio-
metry of APOBEC3F to Gag in Δvif virions.
Materials and methods
Plasmids
pHDV-EGFP (kindly provided by D. Unutmaz, Vanderbilt
University) (Unutmaz et al., 1999), pcDNA-APO3G (kindly
provided by K. Strebel, NIAID, National Institute of Health)
(Kao et al., 2003), and pHCMV-G which expresses the
vesiculostomatitis virus envelope glycoprotein G (VSV-G)
were described previously (Yee et al., 1994).
Table 3
Relative A3G activity in cell lysates
Sample Relative A3G activity a (%) t test b
P value
[C-A3GPBMC]/
[C-A3G2 μg]
c
Cell extracts Total protein used (μg) Exp 1 Exp 2 Exp 3 Average b±SE
From 2 μg A3G transfected 293T 1.8 100.0 100.0 100.0 100.0±0.0
0.9 89.5 84.1 91.5 88.4±2.2
0.45 68.9 60.8 69.8 66.5±2.9
0.225 44.7 41.2 46.3 44.1±1.5
0.113 28.6 23.7 29.1 27.1±1.7
0.056 12.0 14.2 13.1±1.1
293T 1.8 1.1 2.1 1.2 1.5±0.3
PBMC donor #1 0.45 27.2 24.2 29.2 26.9±1.5 <0.001 24.7
PBMC donor #2 0.45 34.9 24.3 37.7 32.3±4.1 <0.001 29.7
PBMC donor #3 0.45 30.9 22.5 31.5 28.3±2.9 <0.001 26.1
Average [C-A3GPBMC]/[C-A3G2 μg] ratio 26.9
a A3G activity in 1.8 μg of protein from 293T cells transfected with 2 μg pcDNA-APO3G was set as 100%. The average cpm for samples containing 1.8 μg of
protein was 54,693; the average cpm for samples without any cell lysates was 57.
b The t tests were performed to compare A3G activities in PBMCs with A3G activities in mock-transfected 293T cells.
c The ratio of A3G activity in PBMCs [C-A3GPBMC] to A3G activity in 293T cells transfected with 2 μg of pcDNA-APO3G [C-A3G2 μg] was calculated by
comparing the A3G activities in 0.45 μg of PBMC cell lysates with the A3G activity in 0.113 μg of 293T cell lysate, because the A3G activity in this 293T sample was
within the linear portion of the standard curve and closest to the A3G activity in the PBMC samples. For example, the [C-A3GPBMC]/[C-A3G2 μg] for PBMC donor #1
was calculated as follows: 26.7%/0.45 μg of PBMC protein /27%/0.113 μg of 293T protein×100%=24.7%.
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293T cells were maintained in Dulbecco's Modified Eagle's
Medium with 10% calf serum as described previously (Svar-
ovskaia et al., 2004). Human PBMCs were isolated from three
different healthy donors through Histopaque (Sigma) gradients,
activated by 2 μg/ml phytohemagglutinin for 3 days, and
maintained in Rosswell Park Memorial Institute 1640 medium
with 10% fetal calf serum and 200 units/ml of recombinant IL-2
(PeproTech) for 3 days. Cells were counted, washed with
phosphate buffered saline (PBS), resuspended in PBS with 2%
fetal calf serum, and the cell concentration was adjusted to 5×106
cells/ml prior to infection. HumanCD4+Tcells were isolated from
activated PBMCs using the CD4 Positive Isolation Kit (Dynal
Biotech), resuspended in fresh mediumwith 200 units/ml of IL-2.Fig. 4. A3G activities in subtilisin-digested virions. Human CD4+T cells were
obtained from three healthy donors and infected with HIV-GFPΔvif virions.
Virions harvested from these virion-producing CD4+T cells were subjected to
subtilisin- or mock-digestions, and subsequently analyzed by SPA. The
incorporation of 3H-dATP using the (UUUA)10 template served as a positive
control, and was set to 100%.Transfection, virus purification, and infection
For determination of A3G stoichiometry in Δvif virions
produced from 293T cells by HPLC analysis, virions were
produced from 293T cells that were transiently transfected with
pHDV-EGFP (20 μg/100-mm-diameter plate) and pcDNA-
APO3G (2, 4, or 8 μg/100-mm-diameter plate) using the
calcium phosphate method (Sambrook and Russell, 2001).
Viruses were harvested 48 h after transfection, filtered through
0.45-μm syringe filters (Corning Inc.), subjected to ultracen-
trifugation through 20% sucrose cushion (w/v) twice, and
concentrated 100-fold by ultracentrifugation as described
previously (Poon et al., 2002).
For determination of A3G stoichiometry in HIV-1 virions
produced from human PBMCs, the cells were first infected with
NL43 or NL43Δvif viruses, which were produced by transient
transfection of 293T cells with pNL43 and pNL43Δvif
expressing plasmids (20 μg/100-mm-diameter plate), respec-
tively, using the calcium phosphate method. Viruses wereTable 4
Quantitation of A3G:Gag ratio in PBMC-derived Δvif virions
Method Comparison Ratio [V-A3GPBMC]
a/Gag
HPLC [V-A3G2 μg]
b / Gag c 1.2%
Cytidine
Deaminase
Assay
[V-A3GPBMC] / [V-A3G2 μg] 19.0%
Calculation [V-A3GPBMC] / [V-A3G2 μg]×
[V-A3G2 μg] / Gag
1.2%×19.0%=0.228%
(1:439)
a [V-A3GPBMC] is defined as average A3G molecules packaged in virions
produced from human PBMCs infected with NL43Δvif virions.
b [V-A3G2 μg] is defined as average number of A3G molecules packaged in
HIV-GFPΔvif virions produced from 293T cells transfected with 2 μg of
pcDNA-APO3G and 20 μg of pHDV-EGFP.
c Gag is defined as average number of HIV-1 Gag molecules present in
virions.
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syringe filters, and the amount of virus associated p24 CA was
quantified by using the HIV-1 P24 ELISA Kit (Perkin Elmer).
For each infection, viruses containing 100 ng of p24 CA were
used to infect 2×106 cells for 24 h in the presence of polybrene
(2 μg/ml). The infected cells were washed three times with PBS,
incubated at 37 °C in medium containing 200 units/ml of IL-2
for 24 h, washed three times with PBS, and incubated for 3 days
in fresh medium containing 200 units/ml of IL-2.
Culture medium containing viruses produced from the
infected human PBMCs was filtered through 0.45-μm syringe
filters, subjected to ultracentrifugation through sucrose cushion
(20% w/v) three times, and concentrated 50-fold as described
previously (Poon et al., 2002). The p24 CA quantities were
determined in the concentrated virus by ELISA and viruses
containing 2 ng of p24 were used for cytidine deamination
assays.
Virions used for immunoblotting analysis and for generating
a standard curve for cytidine deamination activity were
produced from 293T cells transiently transfected with 2 μg of
pcDNA-APO3G (0.5–8 μg/100-mm-diameter plate) and 20 μg
of pHDV-EGFP by the calcium phosphate method, filtered, and
concentrated 20-fold by ultracentrifugation. The p24 CA
quantities in virion preparations were used to quantify the
amounts of virion used in the cytidine deamination assays
(Svarovskaia et al., 2004).
Cytoplasmic protein isolation and immunoblotting analysis
Cytoplasmic proteins from virus producing 293T and human
PBMCs were isolated as described previously (Chen et al.,
2002). The protein concentrations were measured by Bradford
protein assay (Bio-Rad Laboratories). Cytoplasmic proteins and
virus proteins were mixed with 1× SDS protein loading buffer,
denatured at 94 °C for 4 min, separated by electrophoresis on a
12% Tris-Glycine Gel (Invitrogen), transferred to BioTrace
PVDF Transfer Membrane (Pall Corporation), blocked by 5%
milk or SuperBlock TBS (Pierce), probed with murine anti-c-
Myc monoclonal antibody (Sigma) or murine monoclonal
hA3G antibody (Immuno Diagnostics Inc.), and developed by
the SuperSignal West Femto Maximum Sensitivity Kit (Pierce).
Subtilisin digestion of virions
HIV-GFPΔvif virions harvested from in vitro-infected
human PBMCs from three healthy donors were each divided
into two parts and subjected to subtilisin or mock digestion,
respectively. Subtilisin digestion of virions was carried out as
previously described (Ott et al., 1995). Virions were reisolated
by density centrifugation after protease digestion and the A3G
activities present in the preparations were determined.
SPA for A3G activity
The assay was performed as described previously (Svar-
ovskaia et al., 2004). A (UUUA)10 oligonucleotide template
was used in polymerization reaction and served as a positivecontrol. The incorporation tritium-labeled deoxynucleotide
triphosphates was quantified using Tricard 1600TR (Packard)
liquid scintillation analyzer.
HPLC separation and analysis of viral proteins
Virus samples were disrupted in 8 M guanidine–HCl
(Pierce,) with 50 mM dithiothreitol (Calbiochem,) and
fractionated by HPLC to isolate viral proteins. HPLC was
performed at a flow rate of 300 μl/min on 2.1×100 mm
Poros R2/H narrow bore column (Applied Biosystems Inc.),
using aqueous acetonitrile/trifluoroacetic acid solvents and a
Shimadzu HPLC system equipped with LC-10AD pumps,
SCL-10A system controller, CTO-10AC oven, FRC-10A
fraction collector, and SPD-M10AV diode array detector. The
gradient of buffer B (0.1% trifluoracetic acid in acetonitrile)
was: 10−36.5%, 12 min; 36.5−37%, 4 min; 37−41%, 7 min;
41−70%, 12 min; and 70%, 5 min. The temperature was
maintained at 55 °C during HPLC separation. Peaks were
detected by UV absorption at 206 and 280 nm and analyzed
by sequencing using an automated Applied Biosystems Inc.
477 Protein Sequencer and immunoblotting analysis. Quanti-
tation of purified proteins was performed by amino acid
analysis using a Hitachi L-8800 Amino Acid Analyzer.
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